← Back to all trials
Recruiting
NCT07532902
A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer
Conditions: Diffuse Pleural Mesothelioma, Gastroesophageal Carcinoma, Urothelial Carcinoma
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE1
Enrollment: 60
Sponsor: Memorial Sloan Kettering Cancer Center
Location: Memorial Sloan Kettering Basking Ridge (All Protocol Activities) Basking Ridge New Jersey
Summary
The researchers are doing this study to test the safety of BMS-986504 in combination with standard disease-specific anticancer medication in people with metastatic/advanced unresectable MTAP-deleted solid tumor cancer.
Eligibility Criteria
Inclusion Criteria:
* Documentation of Disease:
* Patients must have pathologic confirmation of one of three diseases:
* Diffuse pleural mesothelioma (DPM)
* Gastroesophageal carcinoma (GEC) including adenocarcinoma or squamous cell carcinoma of the esophagus, gastroesophageal junction, or stomach.
* PD-L1 CPS ≥1 (using clone 73-10, DAKO)
* HER2 overexpression negative (using clone 4B5, Ventana): HER2 IHC 0-1+, or HER2 2+ with ISH showing HER2:CEP17 ratio \
Source: ClinicalTrials.gov (NCT07532902). StuddyBuddy aggregates publicly available trial information.
